Cat. #162378
Anti-PCNA monoclonal antibody [16D10]
Cat. #: 162378
Sub-type: Primary antibody
Target: Proliferating Cell Nuclear Antigen (PCNA)
Class: Monoclonal
Application: IP
Reactivity: Human
Host: Rat
£300.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Institute: Helmholtz Munich Core Facility Monoclonal Antibodies
Primary Citation: Spada et al. 2007. J Cell Biol. 176(5): 565-71. PMID: 17312023
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: Anti-PCNA monoclonal antibody [16D10]
- Alternate name: Anti PCNA (clone 16D10)
- Cancer type: Breast cancer
- Research fields: Cancer;Cell biology
- Clone: 16D10
- Tool type ecom: Antibody
- Tool sub type: Primary antibody
- Class: Monoclonal
- Conjugation: Unconjugated
- Reactivity: Human
- Host: Rat
- Disease: Cancer
- Application: IP
- Description: Antibody for PCNA (proliferating cell nuclear antigen), a key protein involved in cell cycle regulation, particularly during DNA replication and repair. Its dysregulation is linked to cancer development.
- Immunogen: Recombinant 6xHis-tagged PCNA
Target Details
- Target: Proliferating Cell Nuclear Antigen (PCNA)
- Target alternate names: Cyclin, DNA Polymerase Delta Auxiliary Protein, ATDL2
- Target background: PCNA (Proliferating Cell Nuclear Antigen) is a sliding clamp for DNA polymerases during DNA replication that coordinates the orderly duplication of the genome by increasing the processivity of DNA polymerase delta. PCNA weighs approximately 29 kDa and forms a homotrimeric ring structure. It is expressed in the nucleus of cells found at high levels in proliferating cells.
Applications
- Application: IP
References
- Spada et al. 2007. J Cell Biol. 176(5): 565-71. PMID: 17312023
![Anti-CAR Whitlow Linker [1C3C3]](https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-300x322.jpg 300w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-280x300.jpg 280w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-954x1024.jpg 954w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-768x824.jpg 768w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025.jpg 1193w)
